CeriBell, Inc. (NASDAQ:CBLL) Director Sells $342,800.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director Rebecca B. Robertson sold 20,000 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $17.14, for a total transaction of $342,800.00. Following the transaction, the director now owns 28,675 shares of the company's stock, valued at $491,489.50. The trade was a 41.09% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

CeriBell Price Performance

Shares of CBLL traded up $0.52 during trading hours on Tuesday, hitting $17.74. 428,767 shares of the company were exchanged, compared to its average volume of 281,677. The company has a debt-to-equity ratio of 0.11, a quick ratio of 16.81 and a current ratio of 17.36. CeriBell, Inc. has a fifty-two week low of $10.01 and a fifty-two week high of $32.75. The firm's fifty day moving average is $16.54 and its 200 day moving average is $20.94.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. The firm had revenue of $20.49 million for the quarter, compared to analyst estimates of $19.30 million. On average, equities analysts predict that CeriBell, Inc. will post -2.46 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC acquired a new position in shares of CeriBell during the fourth quarter worth $128,120,000. TPG GP A LLC bought a new position in CeriBell in the fourth quarter valued at about $102,677,000. Red Tree Management LLC acquired a new position in shares of CeriBell in the fourth quarter valued at approximately $57,083,000. Yu Fan bought a new position in CeriBell in the 4th quarter valued at approximately $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd bought a new position in CeriBell in the 4th quarter valued at approximately $28,160,000.

Wall Street Analyst Weigh In

CBLL has been the topic of several recent analyst reports. LADENBURG THALM/SH SH assumed coverage on CeriBell in a research report on Friday, April 4th. They set a "buy" rating and a $32.00 price target on the stock. Canaccord Genuity Group reissued a "buy" rating and set a $33.00 price target on shares of CeriBell in a report on Wednesday, February 26th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, CeriBell has a consensus rating of "Buy" and an average price target of $32.50.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.